(-)-[[4-(1,4,5,6-tetrahydro-4-m ethyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]propanedinitrile

• US 5,569,657 A
• Filed: 05/31/1995
• Issued: 10/29/1996
• Est. Priority Date: 01/03/1991
• Status: Expired due to Term

• Current Assignee: Orion Corporation (Smiths Group International Holdings Ltd.)
• Original Assignee: Orion-Yhtyma OY
• Inventors: Haikala, Heimo, Nore, Pentti, Honkanen, Erkki, B ackstr om, Reijo, Haarala, Jorma, Wikberg, Tom
• Primary Examiner(s): Daus, Donald G.
• Application Number:
  US08/454,856
• Time in Patent Office: 517 Days
• Field of Search: 544/239, 514/247
• US Class Current: 514/247
• CPC Class Codes: A61P 9/08 Vasodilators for multiple indications
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: C07D 237/04 having less than three double bonds between ring members or between ring members and non-ring members

Abstract

The compound (-)-[[4-(1,4,5,6 tetrahydro-4-methyl-6-oxo-3 pyridazinyl) phenyl]-hydrazono] propane dinitrile and its salts are prepared and used for treating congestive heart failure.

Claims

1. (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile and pharmaceutically acceptable salts thereof.

2. A pharmaceutical composition which comprises a therapeutically effective amount of the compound according to claim 1 and a pharmaceutically acceptable carrier.

3. A method for treating congestive heart failure in a mammalian organism, said method comprising administering an effective amount to treat congestive heart failure of a compound as claimed in claim 1 to a mammalian organism in need of such treatment.